logo
  

Schrdinger Reports FDA Clearance Of IND For SGR-1505

Schrdinger, Inc. (SDGR) announced the FDA cleared its investigational new drug application for MALT1 inhibitor, SGR-1505. The company plans to initiate a phase 1
trial of SGR-1505 in patients with relapsed or refractory B-cell lymphoma in the second half of 2022.

The company said the planned multi-center, dose-escalation study will be conducted in
patients with relapsed or refractory B-cell malignancies to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary signals of therapeutic activity of SGR-1505 as a monotherapy.

SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 inhibitor that was discovered using Schrdinger's physics-based computational platform.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Luxury electric car maker Tesla Inc. has produced more than 3 million vehicles, of which 1 million in Shanghai Gigafactory, according to its founder and Chief Executive Officer Elon Musk. In a tweet on Sunday, Musk said, "Congrats Giga Shanghai on making millionth car! Total Teslas made now over 3M." King's Hawaiian is recalling its Pretzel Slider Buns, Pretzel Hamburger Buns and Pretzel Bites products as they contain one ingredient already recalled by Lyons Magnus, the U.S. Food And Drug Administration said. The Pretzel recall was initiated out of an abundance of caution after one of its supplier Lyons Magnus recently called back various nutritional and beverage products. German consumer goods maker Henkel AG & Co. reported Monday weak profit in its first half amid increasing costs, despite growth in sales. Further, the company maintained its adjusted earnings forecast for fiscal 2022, but raised outlook for organic sales growth.For fiscal 2022, the company continues to expect adjusted earnings per preferred share to decline in the range of 15 percent to 35 percent
RELATED NEWS
Follow RTT